SHERATON BOSTON HOTEL AND THE JOHN B. HYNES VETERANS MEMORIAL CONVENTION CENTER PROGRAM. Early Registration Deadline: April 11, 2017

Transcription

1 ISPOR 22ND ANNUAL INTERNATIONAL MEETING ISPOR BOSTON MAY 20-24, 2017 / BOSTON, MA, USA SHERATON BOSTON HOTEL AND THE JOHN B. HYNES VETERANS MEMORIAL CONVENTION CENTER PROGRAM Evidence and Value in a Time of Social and Policy Change Early Registration Deadline: April 11, 2017 #ISPORBoston Trending Topics: Real-World Evidence Value Frameworks Comparative Effectiveness Research Clinical Outcomes Assessment Patient Preferences and Engagement Modeling Economic Evaluation Use of Health Policy in Decision Making Rare Disease Personalized Medicine Medical Devices Oncology Vaccines Medication Adherence Last year s Annual International Meeting hosted nearly 3,800 attendees from 83 countries and facilitated more than 1,800 presentations! Join colleagues and hear from renowned experts in the HEOR field! ISPOR is recognized globally as the leading scientific and educational organization for health economics and outcomes research (HEOR) and its use in health care decisions. Learn about different and innovative applications in the conduct and use of HEOR. Engage with recognized global experts in the field. Network with colleagues, collaborators, and clients. Share your research and ideas with other ISPOR members in an open and objective environment. Stay current on emerging trends in health care. Advance your career by being an active participant, i.e., attend an ISPOR Short Course or network with recognized leaders in HEOR. Why Attend an ISPOR Meeting? ISPOR meetings provide a forum for discussion and dissemination of HEOR information. These events bring together experts in the field to share innovative research methods and health policy developments and provide an opportunity to network, collaborate, and learn from each other. Held during a time of change, ISPOR Boston will examine drug development, regulatory issues, and decision making through the lens of Evidence and Value in a Time of Social and Policy Change. Who Attends ISPOR Meetings? The ISPOR scope and sphere of influence includes the international HEOR community of global leaders, policy makers, regulators, researchers, academicians, payers, decision makers, patients, and patient groups. This multistakeholder group is invested in using science and research to make better health care decisions.

2 Make the most of ISPOR Boston! ISPOR would like to thank the current event sponsors of ISPOR Boston: (Sponsors as of February 2017) PLATINUM LEVEL: Complete HEOR Solutions (CHEORS), HealthCore Inc., Pharmerit International, and STATinMED Research GOLD LEVEL: Evidera and Precision for Value SILVER LEVEL: BaseCase Management GmbH, Boston Health Economics, Genesis Research, and Johnson & Johnson BRONZE LEVEL: The CPRH Exam and ZRx Outcomes Research Interested in becoming an Event Sponsor? See Event/Sponsorship Opportunities/2017Boston. page 2 #ISPORBOSTON Program New Format! You asked. We listened. New scheduling format for ISPOR sessions! In response to feedback from meeting attendees, ISPOR is implementing a new scheduling format for non-plenary sessions. Specific topics of interest (e.g., modeling, PROs, HTA, etc.) will now be available at multiple session times and in a variety of presentation formats (e.g., issue panels, workshops, and podium presentations). The objective is to give attendees the opportunity to concentrate on their preferred areas of interest by offering a greater diversity of topics and presentation types in each session time frame. We hope this new scheduling format better meets your needs so that you get the most out of your ISPOR meeting experience. ISPOR Boston features more than 1,850 presentations! - Pre-Meeting Short Courses are training courses offered in 7 HEOR topic areas. They range in skill level from introductory to advanced, and continuing education credits are available. Separate registration is required. - Plenary Sessions feature thought-provoking presentations on controversial or challenging topics relating to HEOR methodology issues, the application of HEOR in health care decision making, and health policy. - Issue Panels (IP) introduce debate with multistakeholder perspectives on new or controversial issues in HEOR. - Workshops (W) discuss new and innovative applications in the conduct and use of HEOR or the latest on real-world data, clinical, economic, or patient-reported outcomes, patient preferences, and health care policy. - ISPOR Forums (F) are presented by ISPOR Groups on country/regional health policy, scientific research/initiatives, good practices for outcomes research, research tools, or publications. - Podium Presentations (P) sessions consist of four 15-minute outcomes research presentations on a single topic (e.g., medication compliance, budget impact, cancer outcomes studies). - Poster Presentations sessions contain approximately 400 research posters per session arranged by disease, topic, or health care intervention with an hour for author discussion. - Symposia are sponsored presentations that relate to ISPOR s mission. The sponsor organization chooses a subject of interest to delegates and arranges suitable speakers. Networking Connect with ISPOR members, colleagues, collaborators, and clients! - Meet with clients and other attendees. Schedule meetings via the ISPOR Boston mobile app and web platform (available approximately one month prior to the meeting). - Let the good times roll! Join your ISPOR colleagues for a night of bowling, billiards, and bites at the ISPOR Social Event on Tuesday evening at Lucky Strike Boston, located steps from Fenway Park. Separate registration required. - Engage in session discussions with colleagues during the morning and afternoon coffee breaks or during lunch in the Poster and Exhibit Hall. - Explore the Exhibit Hall and find products and services that meet your needs. ISPOR Groups Collaborate with members of your ISPOR groups. - ISPOR Regional Groups (Chapters, Networks, and Consortia): Join the educational, research, and policy-related activities of these groups and meet other HEOR professionals in your region of the world. - ISPOR Scientific and Health Policy Working Groups (Task Forces, Special Interest Groups, and Council Working Groups): Collaborate with members of these groups and participate in the development of ISPOR knowledge products, such as ISPOR Good Practices for Outcomes Research Reports, manuscripts for Value in Health, and online tools used by decision makers and researchers around the world. - Students: Network with student members worldwide! Join us at the Student Research Competition, Student and Faculty Icebreaker Reception, Student Research Showcase, Student Forum, and Student Roundtable all highly attended events! If you are interested in starting a Student Chapter at your University, see for more information.

3 Plenary Sessions Featured at ISPOR Boston First Plenary Session: Where is US Health Policy Going? This plenary session will comprise four leading health economists in the US (two who have advised Democrats and two who have counseled Republicans) to discuss key topical health policy issues facing the US and the world. The panelists will not present slides, but instead will participate in a moderated discussion. After brief opening statements on the economists response to what worries them the most about health policy going forward?, the discussion will touch upon several key topics: the future of Obamacare and health insurance in the US; drug pricing; health spending trends; and payment and delivery reforms. Moderator: Peter Neumann, ScD, Tufts Medical Center, Boston, MA, USA; Speakers: Jonathan Gruber, PhD, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA; David M. Cutler, PhD, Harvard University, Cambridge, MA, USA; Gail R. Wilensky, PhD, Project HOPE, Bethesda, MD, USA; Joseph R. Antos, PhD, American Enterprise Institute (AEI), Washington, DC, USA Second Plenary Session: Social Network Interventions and Population Health Human beings choose their friends, and often their neighbors and co-workers, and we inherit our relatives; and each of the people to whom we are connected also does the same, such that, in the end, we humans assemble ourselves into large face-to-face social networks which we have recently taken online as well. How and why do we do this? And how might an understanding of human social network structure and function be used to intervene in the world? During this session, Dr. Nicholas Christakis will review recent research from his lab describing two classes of interventions involving both offline and online networks that can help make the world better: (1) interventions that rewire the connections between people, and (2) interventions that manipulate social contagion. Social contagion interventions modify the flow of desirable or undesirable phenomena between people, ranging from obesity to smoking cessation to altruism to pathogens to medication choice. Dr. Christakis will illustrate what can be done using a variety of experiments in settings as diverse as fostering health behavior change in developing world villages, fostering cooperation in networked groups online, facilitating the diffusion of innovation or coordination in groups, and other examples. By taking account of people s structural embeddedness in social networks, and by understanding social influence, it is possible to intervene in social systems to enhance desirable population-level properties as diverse as health, wealth, cooperation, coordination, and learning. Moderator: Shelby D. Reed, RPh, PhD, Duke University, Durham, NC, USA; Speaker: Nicholas A. Christakis, MD, PhD, MPH, Yale University, New Haven, CT, USA Third Plenary Session: When Do We Really Need Randomized Controlled Trials? Virtually all scientists would agree that, everything else being equal, randomized study designs have stronger internal validity than comparable observational study designs. But does it necessarily follow that results from observational studies are unreliable in guiding treatment decisions and policy choices? This plenary session will address how big data is changing the strength of evidence in observational studies and how this is influencing the types of studies where randomization is necessary. How does the ability to link data from multiple sources (such as medical claims, electronic medical records, sociodemographic data, etc.) affect our confidence in drawing causal inferences from observational data? Does it help to reduce missing variable bias? Or does it introduce bias because the people that link are atypical? What is the evidence that observational studies can replicate the average treatment effects from randomized studies conducted on similar populations to answer similar questions? How do considerations of study cost, speed to answer, feasibility, sample size, and other factors influence study design? This panel of leading researchers and policy experts will provide state-of-the-art viewpoints on the usefulness of big data for health care policy decisions and discuss the challenges remaining. Moderator: William Crown, PhD, OptumLabs, Boston, MA, USA; Speakers: Steven Goodman, MD, MHS, PhD, Stanford University School of Medicine, Stanford, CA, USA; Sebastian Schneeweiss, MD, ScD, Harvard Medical School and Brigham & Women s Hospital, Boston, MA, USA MEETING PROGRAM COMMITTEE ISPOR thanks the Meeting Program Committee for its contributions in developing the scientific community s leading HEOR program. PROGRAM COMMITTEE CO-CHAIRS William Crown, PhD, OptumLabs, Boston, MA, USA Peter Neumann, ScD, Tufts Medical Center, Boston, MA, USA RESEARCH REVIEW COMMITTEE CO-CHAIRS Rajender R. Aparasu, PhD, University of Houston, Houston, TX, USA Jan B. Pietzsch, PhD, Wing Tech Inc., Irvine, CA, USA Laura T. Pizzi, PharmD, MPH, Rutgers University, Piscataway, NJ, USA Brian Seal, PhD, RPh, MBA, Takeda Pharmaceuticals, Boston, MA, USA ISSUE PANEL REVIEW COMMITTEE CO-CHAIRS Suzanne Belinson, PhD, MPH, Blue Cross Blue Shield Association, Chicago, IL, USA Newell McElwee, PharmD, MSPH, Merck, Philadelphia, PA, USA Catherine Tak Piech, PhD, Janssen Scientific Affairs, Titusville, NJ, USA WORKSHOP REVIEW COMMITTEE CO-CHAIRS Sachin Kamal-Bahl, PhD, Pfizer, Philadelphia, PA, USA Nneka Onwudiwe, PharmD, PhD, MBA, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA David Vanness, PhD, University of Wisconsin, Madison, WI, USA #ISPORBOSTON page 3

4 Pre-Meeting Short Course Program The ISPOR Short Course Program, offered in conjunction with ISPOR meetings around the world as a series of 4- and 8-hour training courses, is designed to enhance your knowledge in seven topic areas ( Tracks ) related to health economics and outcomes research. Short courses (many with hands-on training opportunities) range in level from introductory to advanced and are taught by leading experts in the field. Separate Short Course registration is required! Short Courses are offered on Saturday, May 20 and Sunday, May 21 in the following topic areas: Economic Methods Introduction to Pharmacoeconomics Cost-Effectiveness Analysis Alongside Clinical Trials Statistical Methods in Economic Evaluations Budget Impact Analysis I: A 6-Step Approach Budget Impact Analysis II: Applications & Design Issues Modeling Methods Bayesian Analysis Overview and Applications Introduction to Modeling Methods Modeling: Design and Structure of a Model NEW! Using Dynamic Simulation Models for Decision Making in Health Care Delivery Using DICE Simulation for Health Economic Analyses Advanced Decision Modeling for Health Economic Evaluations Advanced Topics in Decision Analytic Modeling Observational Data Methods Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources Applications in Using Large Databases Use of Propensity Scores in Observational Studies of Treatment Effects Use of Instrumental Variables in Observational Studies of Treatment Effects Introduction to Big Data Analysis: Graph Analytics Outcomes Research Methods Meta-Analysis and Systematic Reviews in Comparative-Effectiveness Research Network Meta-Analysis Patient-Preference Methods Introduction to Conjoint Analysis Utility Measures NEW! Collecting Health-State Utility Estimates for Economic Models in Clinical Studies Patient-Reported Outcomes Methods Introduction to Patient-Reported Outcomes Advanced Patient-Reported Outcomes Patient-Reported Outcomes Item Response Theory Use of Pharmacoeconomic/Economic/ Outcomes Research Information Interoperability and Informatics Practical Tools and Strategies for Analyzing Real World Data Elements of Pharmaceutical/Biotech Pricing I Introduction Case Studies in Pharmaceutical/Biotech Pricing II Advanced Risk-Sharing/Performance-Based Arrangements for Drugs and Other Medical Products NEW! US Payers An Introduction to Their Structures, Evidence Needs, and Decision-Making Process Using Multi-Criteria Decision Analysis in Health Care Decision Making: Approaches & Applications Select courses require the use of your personal laptop. SHORT COURSE FEES ALL DAY COURSES Standard: $700 Clinical/Government/Academia: $500 Full-Time Students: $150 Standard: $800 Clinical/Government/Academia: $600 Full-Time Students: $200 HALF DAY COURSES Standard: $350 Clinical/Government/Academia: $250 Full Time Students: $100 Standard: $400 Clinical/Government/Academia: $300 Full-Time Students: $125 MEETING ENHANCEMENT FEES Short Course Continuing Education Accreditation (CPE & CME): $125 See ShortCourses/2017Boston for Short Course schedule and descriptions, as well as to register. page 4 #ISPORBOSTON

5 Meeting Program SATURDAY, MAY 20 8:00AM-5:00PM SHORT COURSES 5:30PM-6:30PM EDUCATIONAL SYMPOSIUM The Evolving Approach to Drug Value Assessment in Global Markets (Sponsored by Health Strategies Group) SUNDAY, MAY 21 8:00AM-5:00PM SHORT COURSES 5:30PM-6:30PM EDUCATIONAL SYMPOSIUM Enabling High-Value Interactions and Value-Based Contracts Between Pharma and Payers Using Claims and EHR Data (Sponsored by Aetion, Inc.) 6:30PM-8:30PM ISPOR STUDENT RESEARCH COMPETITION 6:45PM-7:45PM EDUCATIONAL SYMPOSIUM Prediction and Monitoring of Real-Life Outcomes: The Linchpin in Successful Outcomes-Based Agreements (Sponsored by LASER Analytica) 8:30PM-9:30PM ISPOR STUDENT & FACULTY ADVISOR RECEPTION MONDAY, MAY 22 6:00AM * Program subject to change ISPOR BOSTON 5K RUN 7:15AM-8:15AM EDUCATIONAL SYMPOSIUM Health Economics and Outcomes Research in the Era of Value-Based Care and the 21st Century Cures Act (Sponsored by Cardinal Health Specialty Solutions) 8:30AM-2:00PM POSTERS SESSION I 8:30AM-10:30AM WELCOME & FIRST PLENARY SESSION Where Is US Health Policy Going? 10:30AM-11:00AM BREAK, EXHIBITS & POSTERS SESSION I 11:00AM-12:00PM BREAKOUT SESSION IP1: Future Directions for Cost-Effectiveness Analysis IP2: Joint ISPOR ISPE Special Task Force on RWE in Regulatory Decision Making: Will Transparency Improve Acceptability? IP3: Value Assessment Debate: Pluralistic Approach or Does One Size Fit All? W1: Dealing With the Challenges of Providing Information to Payers Prior to Product Launch P1: Modeling Studies P2: Pricing and Reimbursement Studies 12:00PM-2:15PM LUNCH, EXHIBITS & POSTERS SESSION I 12:30PM-1:30PM EDUCATIONAL SYMPOSIUM Is There a Way to Agree on Evidence Requirements Before Evidence Is Generated? (Sponsored by QuintilesIMS) 12:30PM-1:30PM ISPOR STUDENT RESEARCH SHOWCASE 1:00PM-2:00PM POSTER AUTHOR DISCUSSION HOUR SESSION I 2:00PM-3:00PM NEW PROFESSIONAL EVENT CAREER ADVICE ACROSS THE GLOBE 2:15PM-3:15PM BREAKOUT SESSION IP4: ISPOR s Special Task Force Report on U.S. Value Assessment Frameworks: What Does It Say and Is It Helpful? IP5: Voices and Echoes: What Methods Should We Be Using to Capture the Patient Voice? W2: Actuarial and Health Economic Approaches to Assess Value: Speaking the Same Language or Need for Translation? W3: Developing Cost-Effectiveness Models to Assess Value of Immuno- Oncology Therapies: Challenges and Approaches P3: Infectious and Respiratory Disease Studies P4: Medicare Studies 3:15PM-3:45PM BREAK & EXHIBITS 3:45PM-4:45PM BREAKOUT SESSION IP6: Is There Consistency in the Evidence That Payers Report Reviewing When Determining Drug Coverage? Should It Be Consistent? W4: Minding the Gaps: Combining Patient-Centric Valuation, Observational Data Analysis, and Decision Modeling to Deliver Patient-Centered Comparative Effectiveness Research W5: ISPOR s Special Task Force Report on US Value Assessment Frameworks: A Deeper Dive into Its Health Economic Underpinnings W6: Demystifying Predictive Analytics and an Introduction to Recent Methodological Innovations P5: Cancer Studies P6: Cost of Illness and Resource Utilization Studies 3:45PM-7:45PM POSTERS SESSION II 5:00PM-6:00PM BREAKOUT SESSION IP7: Controversies in Transparency and Sensitivity Recommendations From the Second Panel on Cost-Effectiveness in Health and Medicine IP8: Performance-Based Risk-Sharing Arrangements: What Are the Latest Views from the Negotiating Table? W7: Are Payers Equipped to Assess the Unique Value of Precision and Personalized Medicine (PPM)? Analyzing Current Value Frameworks and Their Application Within the PPM Context W8: Good Practices for Synthesizing and Using Evidence in Health Care Decision Making P7: Personalized Medicine Studies P8: Treatment Patterns Studies 6:00PM-7:45PM EXHIBITORS OPEN HOUSE RECEPTION & POSTERS SESSION II 6:15PM-7:15PM BREAKOUT SESSION F1: Extending Cost-Effectiveness Analysis With Partial Optimization Modelling and Fiscal Modelling in Vaccine Value Assessments F2: How Does Measurement of Multiple Medication Adherence Differ Between Chronic Diseases? F3: New Trends of Health Technology Assessment Development and Value Evidence Requirement for Access and Reimbursement in Asia (China, Japan, South Korea, and Taiwan) F4: Fellowships and Internships: Career Opportunities for the Future F5: Reimbursement of Oncology Drugs in Arabic Countries F6: Evolution of the Process of Health Technology Assessment in Mexico: Medical Devices 6:45PM-7:45PM POSTER AUTHOR DISCUSSION HOUR SESSION II 7:30PM-9:00PM ISPOR GLOBAL NETWORKS RECEPTION #ISPORBOSTON page 5

6 Meeting Program TUESDAY, MAY 23 7:15AM-8:15AM EDUCATIONAL SYMPOSIUM New Developments in Psychometric and Utility Methods for Patient- Reported Outcomes Measurement in Health Economic Evaluations (Sponsored by Analysis Group) 8:30AM-2:00PM POSTERS SESSION III 8:30AM-10:30AM WELCOME & SECOND PLENARY SESSION Social Network Interventions and Population Health 10:30AM-11:00AM BREAK, EXHIBITS & POSTERS SESSION III 11:00AM-12:00PM BREAKOUT SESSION IP9: Perspectives on the Relationship Between Cost-Effectiveness and Affordability IP10: Moving Beyond the QALY in Patient-Centered Value Frameworks: But in What Direction? W9: Report From the ISPOR Value of Information Task Force W10: Improving Reproducibility and Robustness of Evidence From Large Health Care Databases With Specific Reporting Guidance P9: Diabetes Studies P10: Medical Device and Diagnostics Studies 12:00PM-2:15PM LUNCH, EXHIBITS & POSTERS SESSION III 12:30PM-1:30PM EDUCATIONAL SYMPOSIUM FDAMA 114 and the 21st Century Cures Act: Insights From Payers and Manufacturers, and Implications for the Exchange of Health Care Economic Information (Sponsored by Xcenda) 1:00PM-2:00PM POSTER AUTHOR DISCUSSION HOUR SESSION III 1:15PM-2:00PM ISPOR GENERAL BUSINESS MEETING 2:15PM-3:15PM BREAKOUT SESSION IP11: Making Value Frameworks Fit for Purpose to Guide Decisions Is There a Need for Empirical Estimates of Opportunity Costs? IP12: Will the 21st Century Cures Act Drive Conduct of Pragmatic Clinical Trials? W11: Stated Preferences in Drug Evaluation: A Comparative Assessment of the Use of Stated Preference in the US, Canada, and the European Union W12: Opportunities and Challenges in Increasing the Voice of People Affected by Disease in Drug Development, Approvals, and Health Care Technology Assessments: A Case Study in Multiple Sclerosis P11: Cost-Effectiveness Studies P12: Cardiovascular Studies 3:15PM-3:45PM BREAK & EXHIBITS 3:30PM-5:30PM ISPOR STUDENT RESEARCH ADVICE ROUNDTABLE 3:45PM-4:45PM BREAKOUT SESSION IP13: The Complexities of Medicare Directly Negotiating Drug Prices: What Are the Pros and Cons? IP14: Health Care Economic Information: Considerations for Expanding Proactive Communications by Biopharmaceutical Manufacturers to Population Health Decision Makers W13: ISPOR Clinical Outcome Assessment Measurement in Rare Disease Clinical Trials Emerging Good Practices Task Force A Case Study on Application of Final Recommendations page 6 #ISPORBOSTON W14: Title TBD P13: Medication Adherence Studies P14: Patient Preference Studies 3:45PM-7:45PM POSTERS SESSION IV 5:00PM-6:00PM BREAKOUT SESSION IP15: Minimal Clinically Important Difference in EQ-5D: We Can Calculate It But Does That Mean We Should? IP16: FDAMA Section 114 Has Been Replaced by Section 3037 of the Cures Act: Now What? W15: Optimal Allocation of Resources in Managing Medical Device Portfolios W16: The New Wave in Real World Evidence Integrated Datasets P15: Mental Health Studies P16: Research on Methods Studies 6:00PM-7:45PM EXHIBITORS WINE & CHEESE RECEPTION & POSTERS SESSION IV 6:15PM-7:15PM BREAKOUT SESSION F7: Performance-Based Risk Sharing Agreements Opportunities and Challenges for Medical Devices F8: Challenges in Research and Health Technology Assessment of Rare Disease Technologies F9: Health Economic Modeling in Oncology F10: Patient Involvement in Health Technology Assessment in Asia F11: Solving Health Inequities Across Latin America, Beyond Universal Health Coverage F12: Differential Pricing in Resource-Constrained Environments 6:45PM-7:45PM POSTER AUTHOR DISCUSSION HOUR SESSION IV 8:00PM-11:30PM ISPOR SOCIAL EVENT WEDNESDAY, MAY 24 7:30AM-8:30AM EDUCATIONAL SYMPOSIUM Value Is in the Eye of the Beholder: Redefining Market Access Success in a Value-Based Economy (Sponsored by Covance) 8:00AM-1:30PM POSTERS SESSION V 8:45AM-9:45AM BREAKOUT SESSION IP17: Cost-Effectiveness Models for Innovative Oncology Treatments: How Different Methodological Approaches Can Be Used to Estimate the Value of Novel Therapies * Program subject to change

7 Meeting Program IP18: Evaluating Gene Therapies: Ready or Not Here They Come IP19: Toward Open Science for Large Health Care Database Research: Improving Reproducibility and Robustness of Evidence W17: Conducting Qualitative Exit Interviews Following Clinical Trials or Observational Studies: A Valuable Method for Understanding the Patient Experience, Informing Measurement Strategy, and Aiding Interpretation of Patient-Reported Outcomes W18: Numbers or Noise? Quantifying the Internal Validity of Stated-Preference Data W19: Can Research and Evaluation Move the Needle on Telehealth and mhealth? Designing, Conducting, and Disseminating Studies That Increase Understanding of Benefits and Incentives 9:45AM-10:15AM BREAK, EXHIBITS & POSTERS SESSION V 10:15AM-12:00PM WELCOME & THIRD PLENARY SESSION When Do We Really Need Randomized Controlled Trials? 12:00PM-1:45PM LUNCH, EXHIBITS & POSTERS SESSION V 12:30PM-1:30PM EDUCATIONAL SYMPOSIUM Evidentiary Equilibrium: Balancing Real-World Evidence Development With Stakeholder Requirements (Sponsored by Inventiv Health) 12:30PM-1:30PM POSTER AUTHOR DISCUSSION HOUR SESSION V 1:45PM-2:45PM BREAKOUT SESSION IP20: Valuing Precision: How Will Next Generation Diagnostics Change the Landscape for HEOR and Patient Management? IP21: Use of Real-World Evidence to Shape Health Policies for Medical Devices IP22: Measuring What Matters: Is Standardized Outcomes Measurement Necessary to Support Value- Based Care? W20: Biosimilars in the US An Opportunity Lost or in the Making W21: Quantifying Efficiency in Health Care: Time and Motion Methodology to Generate Robust Economic Evidence for Drugs and Medical Devices 2:45PM-3:00PM BREAK 3:00PM-4:00PM BREAKOUT SESSION IP23: What s So Unique About the US? A Comparative US-UK Perspective to Debate the Role of US Health System Characteristics in the Development and Implementation of Value Frameworks IP24: Incorporating Patient Preference Information throughout the Medical Product Lifecycle: What Are the Opportunities and Challenges? W22: A Multi-Stakeholder Collaborative Approach to Developing a Patient-Reported Outcome (PRO) Measure for FDA Drug Development Tool Qualification: The PRO Consortium s Depression Working Group Experience W23: Challenges for Implementation of Regulatory HTA in Japan W24: Analysis and Interpretation of Censored Cost Data Using Real-World Evidence: A Step-by-Step Approach Hotel/Venue Information: The ISPOR 22nd Annual International Meeting will be held at the Sheraton Boston Hotel (39 Dalton Street, Boston, MA, 02199) and John B. Hynes Veterans Memorial Convention Center, located approximately 6 miles (9.5km) from the Boston Logan International Airport and in the heart of the city. Registration and meeting sessions will be held at the Sheraton Boston Hotel. Posters and exhibits will be in the John B. Hynes Veterans Memorial Convention Center (connected to the Sheraton). Discounted room rates are available for ISPOR meeting attendees and reservations can be made online through the Hotel and Venue Information webpage ( org/event/eventinformation/2017boston?p=483). Due to the extensive number of graduations and in-town baseball games, hotel sleeping rooms will be in high demand. Please make your hotel reservation as soon as possible. Early Registration Deadline: April 11, 2017 MEETING REGISTRATION FEES STANDARD MEMBER Member $825 Non-Member $1,000 Member $925 Non-Member $1,100 CLINICAL PRACTITIONERS (CLINICAL PRACTICE, HOSPITAL) Member $600 Non-Member $775 Member $700 Non-Member $875 FULL-TIME GOVERNMENT AND ACADEMIA Member $500 Non-Member $675 Member $600 Non-Member $775 PATIENT REPRESENTATIVE Member $175 Non-Member $350 Member $225 Non-Member $450 FULL-TIME STUDENTS (must provide current enrollment docs) Member $175 Non-Member $235 Member $225 Non-Member $335 ONE DAY REGISTRATION (PER DAY) May 22, May 23, or May 24 Member $400 Non-Member $575 Member $500 Non-Member $675 MEETING ENHANCEMENT FEES ISPOR 5K RUN: Monday, May 22, 5:30AM Member/Non-Member $40 ISPOR SOCIAL EVENT: Tuesday, May 23, 8:00PM-11:30PM Member/Non-Member $75 Student $40 Let the good times roll! Join your ISPOR colleagues for a night of bowling, billiards, and bites at the ISPOR Social Event at Lucky Strike Boston, located steps from Fenway Park. * Program subject to change #ISPORBOSTON page 7

8 ISPOR BOSTON 5K RUN Lace up and start your Monday morning at ISPOR Boston with a run around Castle Island Park! Race fees benefit the Seema S. Sonnad Ph.D. Memorial Fund for Young Investigators THE RUN DOWN: Day: MONDAY MORNING, MAY 22, 2017 Time: RACE STARTS AT 6:00AM Place: CASTLE ISLAND PARK Race fee: $40 Includes: Roundtrip transportation to/from the Sheraton Boston Hotel and Castle Island Park and a Race T-Shirt. REGISTER TODAY Race managed by Mike Linnane, Results Event Management SPONSORED BY: